Kang-Ling Wang1,2, Renato D Lopes3, Manesh R Patel3, Harry R Büller4, Doreen Su-Yin Tan5, Chern-En Chiang1,2, Robert P Giugliano6. 1. General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan. 2. School of Medicine, National Yang-Ming University, Taipei, Taiwan. 3. Duke Clinical Research Institute, Duke University School of Medicine, 2400 Pratt Street, Durham, NC 27710, USA. 4. Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands. 5. Department of Pharmacy, Khoo Teck Puat Hospital, Singapore, Singapore. 6. Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
AIMS: Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta-analysis, we aimed to assess outcomes with reduced-dose NOACs when given as pre-specified in pivotal trials. METHODS AND RESULTS: Aggregated data abstracted from Phase III trials comparing NOACs with warfarin in patients with AF were assessed by treatment using risk ratios (RRs) and 95% confidence intervals (CIs) stratified by patient eligibility for NOAC dose reduction. Irrespective of treatments, annualized rates of stroke or systemic embolism and major bleeding were higher in patients eligible for reduced-dose NOACs than in those eligible for full-dose NOACs (2.70% vs. 1.60% and 4.35% vs. 2.87%, respectively). Effects of reduced-dose NOACs compared with warfarin in patients eligible for reduced-dose NOACs on stroke or systemic embolism [RR 0.84 (95% CI 0.69-1.03)] and on major bleeding [RR 0.70 (95% CI 0.50-0.97)] were consistent with those of full-dose NOACs relative to warfarin in those eligible for full-dose NOACs [RR 0.86 (95% CI 0.77-0.96) for stroke or systemic embolism and RR 0.87 (95% CI 0.70-1.08) for major bleeding; interaction P, 0.89 and 0.26, respectively]. In addition, NOACs were associated with reduced risks of haemorrhagic stroke, intracranial haemorrhage, fatal bleeding, and death regardless of patient eligibility for NOAC dose reduction (interaction P > 0.05 for each). CONCLUSIONS: Patients eligible for reduced-dose NOACs were at elevated risk of thromboembolic and haemorrhagic complications when treated with anticoagulants. NOACs, when appropriately dose-adjusted, had an improved benefit-harm profile compared with warfarin. Our findings highlight the importance of prescribing reduced-dose NOACs for indicated patient populations. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta-analysis, we aimed to assess outcomes with reduced-dose NOACs when given as pre-specified in pivotal trials. METHODS AND RESULTS: Aggregated data abstracted from Phase III trials comparing NOACs with warfarin in patients with AF were assessed by treatment using risk ratios (RRs) and 95% confidence intervals (CIs) stratified by patient eligibility for NOAC dose reduction. Irrespective of treatments, annualized rates of stroke or systemic embolism and major bleeding were higher in patients eligible for reduced-dose NOACs than in those eligible for full-dose NOACs (2.70% vs. 1.60% and 4.35% vs. 2.87%, respectively). Effects of reduced-dose NOACs compared with warfarin in patients eligible for reduced-dose NOACs on stroke or systemic embolism [RR 0.84 (95% CI 0.69-1.03)] and on major bleeding [RR 0.70 (95% CI 0.50-0.97)] were consistent with those of full-dose NOACs relative to warfarin in those eligible for full-dose NOACs [RR 0.86 (95% CI 0.77-0.96) for stroke or systemic embolism and RR 0.87 (95% CI 0.70-1.08) for major bleeding; interaction P, 0.89 and 0.26, respectively]. In addition, NOACs were associated with reduced risks of haemorrhagic stroke, intracranial haemorrhage, fatal bleeding, and death regardless of patient eligibility for NOAC dose reduction (interaction P > 0.05 for each). CONCLUSIONS:Patients eligible for reduced-dose NOACs were at elevated risk of thromboembolic and haemorrhagic complications when treated with anticoagulants. NOACs, when appropriately dose-adjusted, had an improved benefit-harm profile compared with warfarin. Our findings highlight the importance of prescribing reduced-dose NOACs for indicated patient populations. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Serdar Tütüncü; Manuel Olma; Claudia Kunze; Joanna Dietzel; Johannes Schurig; Cornelia Fiessler; Carolin Malsch; Tobias Eberhard Haas; Boris Dimitrijeski; Wolfram Doehner; Georg Hagemann; Frank Hamilton; Martin Honermann; Gerhard Jan Jungehulsing; Andreas Kauert; Hans-Christian Koennecke; Bruno-Marcel Mackert; Darius Nabavi; Christian H Nolte; Joschua Mirko Reis; Ingo Schmehl; Paul Sparenberg; Robert Stingele; Enrico Völzke; Carolin Waldschmidt; Daniel Zeise-Wehry; Peter U Heuschmann; Matthias Endress; Karl Georg Haeusler Journal: J Neurol Date: 2021-10-31 Impact factor: 4.849
Authors: Christian Fastner; Kristina Szabo; Melina Samartzi; Mathieu Kruska; Ibrahim Akin; Michael Platten; Stefan Baumann; Angelika Alonso Journal: PLoS One Date: 2022-02-17 Impact factor: 3.240
Authors: M Cristina Polidori; Mariana Alves; Gulistan Bahat; Anne Sophie Boureau; Serdar Ozkok; Roman Pfister; Alberto Pilotto; Nicola Veronese; Mario Bo Journal: Eur Geriatr Med Date: 2021-11-02 Impact factor: 1.710